ArticleJournal of nanobiotechnology2026
Responsive hydrogel delivery of DFO-programmed apoptotic bodies drives redox-immuno-angiogenic remodeling in diabetic wounds.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Mesenchymal stem cell (MSC)-derived exosomes show clear potential in cell-free regenerative medicine. However, their clinical translation is limited by low production yields and inconsistent therapeutic efficacy. To address this, we actively programmed stem cell apoptosis to generate high-yield, functional extracellular vesicles. By using deferoxamine (DFO) to stabilize HIF-1α prior to UV-induced apoptosis, we produced DFO-programmed apoptotic bodies (DABs). These programmed apoptotic bodies demonstrated a significantly higher production yield than conventional exosomes. Multi-omics analyses revealed that DABs inherit an enriched, pro-regenerative miRNA repertoire that functionally outperforms both native apoptotic bodies and exosomes. Beyond promoting classical angiogenic and migratory signaling, DABs support tissue repair by altering the mitochondrial bioenergetics of recipient cells. To prevent rapid in vivo clearance and address the highly oxidative diabetic microenvironment, we encapsulated DABs within a glucose- and ROS-responsive hydrogel, developing the DABs@PHA-PVA
Indexed as
Identifiers
42881412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.